Lenalidomide news

All news on Lenalidomide (also known as Revlimid): plants, production capacities, investments and involved companies.

7 December 2025

Genmab's Phase 3 Trial Shows EPKINLY + R2 Benefits in Relapsed Follicular Lymphoma

EPKINLY + R2 reduces disease progression risk by 79% in relapsed follicular lymphoma, with a 95% response rate. FDA-approved, it offers a new second-line treatment option.
18 November 2025

Genmab's EPKINLY Combination Approved by FDA for Relapsed Follicular Lymphoma

EPKINLY + R² shows superior progression-free survival and response rates in Phase 3 trial for relapsed follicular lymphoma, with a consistent safety profile.

Who will be producing Lenalidomide in the future?

Find out with chemXplore Analytics